---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046583"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:44:40.053395+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q3 2024 cash $39M; extends runway into 1Q2026 on $65M in financings

## Summary
- Cash and restricted cash $39.0M as of Sept 30, 2024, vs $39.5M at Dec 31, 2023.
- Closed $30M debt and $35M equity financings in Q3, extending cash runway into 1Q2026.
- Total operating expenses $14.4M (R&D $8.1M, G&A $6.3M) vs $16.1M in Q3 2023.
- OCU400 Phase 3 liMeliGhT trial for RP on track to complete enrollment in 1H2025.
- OCU410 Phase 2 recruiting; OCU410ST DSMB approved Phase 2; OCU200 IND cleared for Phase 1.

## SEC filing metadata
- accession: 0001628280-24-046583
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828024046583/0001628280-24-046583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828024046583/ocgn-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046583
- JSON: https://secwatch.observer/filing/0001628280-24-046583.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046583.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.